Abstract
Objective-To examine further the effect of using two view mammography in comparison with one view mammography in the detection of small «15 mm) invasive cancers for programmes in the National Health Service breast screening programme (NHSBSP). The study is in two parts: first the effect on the small invasive cancer detection rate for programmes that changed from using one view to two views for first (prevalent) screens, and secondly the effect on the small invasive cancer detection rate for programmes that used two views for subsequent (incident) screens compared with programmes that used one view. Setting-Screening programme data from theNHSBSP. Methods-Data were collated from all screening programmes in the United Kingdom on standard "Korner" returns (KC62 forms) for the screening years 1 April 1994 to 31 March 1995 and 1 April 1995 to 31 March 1996. The comparison between one and two view mammography was made using indirectly age standardised invasive cancer detection rates. Results-For prevalent (first) screens, programmes changing from one view mammography in 1994/95 to two views in 1995/96 reported a 45% (95% confidence interval (CI) 25% to 68%) increase in the detection of invasive cancers of <15 mm. In comparison, programmes that were already using two views in 1994/95 showed no change in 1995/96. For incident (subsequent) screens the small number of programmes that have opted to use two views reported 25% (95% CI 1% to 55%) more invasive cancers of < 15 mm than programmes using one view in 1995/96, and 42% (95% CI 11% to 81%) more in 1994/95. Conclusions-These results confirm the benefit of using two view mammography in the detection of small invasive cancers, and provide evidence that this effect is seen in subsequent screens as well as the first screen.
Since 1 August 1995 all screening programmes in the National Health Service breast screening programme (NHSBSP) have been using two view (mediolateral oblique plus craniocaudal) mammography for prevalent (first) screens. A recent randomised controlled trial demonstrated that two view mammography detected 24% more invasive cancers than only one view. 1 More recently we published a paper showing that, using data from all screening programmes in the NHSBSP for the screening year 1 April 1994 to 31 March 1995, for prevalent screens, programmes opting to use two views detected 42% more small invasive cancers «15 mm), but only 7% more larger invasive cancers and 3% more non-invasive cancers." These results suggest that using only the invasive cancer detection rate or the overall cancer detection rate (including non-invasive cancers) is likely to dilute the importance of using two view mammography in terms of likely mortality reduction. This is because a high mortality reduction is likely to depend on the detection oflarge numbers of small invasive cancers which have not yet rnetastasised.'
All screening programmes had changed to using two view mammography by, at the latest, 1 August 1995 for prevalent screens. Consequently during the screening year 1 April 1995 to 31 March 1996 all programmes used two views for all or most of the screening year. This has enabled us to examine whether the expected increase in the detection of small invasive cancers occurred in those programmes that changed from one view to two views. From our previous work" we would expect a 42% increase in the detection of small invasive cancers « 15 mm). At the same time the programmes already using two views in 1994/95 act as a form of control group, as we would not expect a large increase in the detection of small invasive cancers for this group (unless other unknown factors were operating).
Methods
The basic methods have been discussed in the earlier paper," although they will be briefly reviewed here. The information on the detection of invasive cancers was taken from the KC62 forms, returned to the Department of Health and the Cancer Screening Evaluation Unit every screening year. To allow for the NB Size was unavailable for some invasive cancers. The SDR for cancers < 15 mm and" 15 mm will therefore be marginally low. SDR = standardised detection ratio. NB Size was unavailable for some invasive cancers. The SDR for cancers < 15 mm and " 15 mm will therefore be marginally low. SDR = standardised detection ratio.
confounding effects of age, indirect age standardisation was used to produce the standardised detection ratio' 5 (SDR), which is the ratio of the observed number of invasive cancers to the expected number of invasive cancers, applying criteria from the Swedish two county randomised controlled trial. The actual expected rates for each age band for prevalent and incident screens are shown in the appendix. Where necessary, to allow for any confounding effect of the background incidence of breast cancer in the catchment area of each screening programme, correction factors were produced using the Atlas of Cancer Incidence 1968-85: Two further measures used are the SDR for small «15 mm) invasive cancers, and the SDR for large (~15 mm) invasive cancers. The expected number for each measure is half of the total number of expected invasive cancers, based on the observation that the Swedish two county study detected approximately 50% of all invasive cancers as less than 15 mm, for both prevalent (first) screens and incident (subsequent) screens. confidence interval (Cl) 16% to 42%) increase in detection. The largest increase was seen in the detection of smaller invasive cancers with the SDR «15 mm) increasing from 0.79 to 1.14, an increase of 45% (95% CI 25% to 68%). A smaller increase was seen in larger invasive cancers with the SDR (~15 mm) increasing from 0.87 to 1.06, an increase of 22% (95% CI 5% to 41 %). It should be noted that the SDR for both small and large cancers will be slightly low as a small number of invasive cancers were not sized on the return forms.
Results

PREVALENT (FIRST) SCREENS
As a comparison, table 2 shows the results of screening programmes that were already using two view mammography in 1994/95 and continued to do so in 1995/96. The SDR for all invasive cancers increased from 1.04 to 1.08, an increase of 4% (95% CI -4% to 13%). The SDR for small invasive cancers remained the same, although there was an increase in the detection oflarge invasive cancers of 15%.
The recall rate for the first invitation to screening for programmes that changed to two views was 8.5% in 1994/95 and 8.1 % in 1995/ 96. In comparison those programmes using two views for both 1994/95 and 1995/96 had recall rates of 6.2% and 6.7% respectively.
INCIDENT (SUBSEQUENT) SCREENS
For incident screens, only four programmes opted to use two views in 1995/96. Evaluating incident screen invasive cancers is more complicated than prevalent screens.' The rates shown in the appendix are based on a screening programme with a prevalent screen SDR of 1 (three years earlier than the incident screen), with no cancers detected through early recall, and which uses a three year screening period. Almost all screening programmes in the NHSBSP do use such a period, and only a relatively small number of invasive cancers are detected through early recall. The criterion that the prevalent SDR should have been 1 three years earlier-that is, in 1992/93 for 1995/96 incident screens-is not in general met by most screening programmes. If a screening programme detected fewer invasive cancers than expected at the prevalent screen, then a small number of additional invasive cancers will be detectable at the incident screen, as all false negative cancers do not appear as interval cancers within three years.' However, considering the SDR results for prevalent screens for 1992/93, the SDR of the four screening programmes that used two views for incident screens in 1994/95 was 0.84, and for all other programmes the SDR was 0.80. These figures are so dose that we can assume that the small additional numbers of cancers detectable at the incident screens in 1995/96 compared with the calculated expected rates will be equivalent. We can therefore compare the SDRs achieved by the two groups. Table 3 shows the results of this comparison for 1995/96 and table 4 for 1994/95. For 1995/ 96, programmes using two views had an SDR for all invasive cancers of 1.06 compared with 0.86 for programmes using only one view, the increase in detection being 23% (95% CI 5% to 44%). Again the biggest effect was seen for small invasive cancers, with programmes using two views reporting an SDR of 1.15 compared with 0.92 reported by programmes using one view. This represents a 25% (95% CI 1% to 55%) increase in the detection of small invasive cancers. Programmes using two views also detected 23% more larger invasive cancers (95% CI -2% to 56%). For 1994/95 the programmes using two views detected 27% (95% CI 6% to 53%) more invasive cancers, with again the biggest increase being for small invasive cancers, 42% (95% CI 11% to 81 %).
Discussion
This study demonstrates that the expected increase in the detection of small invasive cancers in programmes that changed from using one view to two view mammography for prevalent screens did occur, and at the level expected-that is, 45% compared with the 42% increase predicted.' The results also suggest that the learning curve for radiologists moving from one view to two views is negligible in producing an increase in the detection of invasive cancers. However, the lower recall rates expected from using two view mammography were not seen. These data may indicate a longer learning curve with regard to the lowering of recall rates with the use of two views. The data for 1996/97 will be used to assess the recall rates of those programmes that changed. That a statistically significant increase in the detection of small invasive cancers was demonstrated from only four screening programmes opting to use two view mammography for incident screens may be indicative of the importance of the use of two view mammography. However, any results based on only four screening programmes must be treated with some caution. The increase for both prevalent and incident screens is, however, consistent and provides suggestive evidence that there is no major difference with regard to the efficacy of using two view mammography for these screens. The detection of small invasive cancers is the main reason for breast cancer screening, because it is the detection of these tumours that will lead to a large reduction in mortality.' There are a number of reasons why the effect of using two views may be becoming more apparent. First, most programmes within the NHSBSP now use a film density in the range l.4D to 1.8D which has been shown to give the maximum image quality." Using much lower film densities-for example, 0.8D or Blanks, Moss, Wallis 0.9D-results in poorer image quality (although a lower radiation dose) and the benefit of using two views may be less pronounced." Secondly, much previous work has considered only the overall cancer detection rate (including ductal carcinoma in situ (DCIS)), and the benefit of using two views, which is less for detecting larger invasive cancers and DCIS 2 will be diluted. Thirdly, with regard to the NHSBSP, work on the small invasive cancer detection rate in earlier years was made difficult because a much larger percentage of invasive cancers did not have size recorded on the KC62 return forms.
Advances in methods-for instance, the use of two views and a film density between 1.4D and 1.8D-and (probably) increasing experience are resulting in increases in SDRs which would suggest that, for prevalent screens, interval cancers in women screened from screening years starting from 31 March 1994 onwards should be similar, and from 31 March 1995, possibly lower than those achieved by the Swedish two county study. A full enumeration of these interval cancers will not, however, be available until at least 1998 or 1999. To date, interval cancer rates reported by regions have been considerably in excess of the rates achieved by the Swedish two county study." 11 However, these rates relate to women screened in the early years of the national programme, i.e 1988-1992, because of the length of time required for interval cancers to occur (up to three years after a negative screen) and be enumerated. It cannot be emphasised enough that any improvements in cancer detection rate as the result of changing from say one view to two view mammography at the start of a screening year will take up to one and half years to be enumerated via KC62 return forms, up to five years to translate into a measurable reduction in interval cancer rates, and up to eight to ten years to result in an additional reduction in mortality.
These results reported here provide suggestive evidence that if the NHSBSP were to move to the use of two view mammography for all incident screens as well as prevalent screens, then the overall invasive cancer detection rates achieved by the NHSBSP may well be in excess of those achieved by the Swedish two county study. Interval cancer rates would then be expected to be lower and mortality reduction in the screened group higher than that achieved by the Swedish two county study. Appendix Table 5 shows the expected rates per 1000 women screened within each age band reported on KC62 return forms, based on the application of criteria from the Swedish two county study to England and Wales background rates.' Note that because the expected rate increases rapidly with age, particularly for prevalent screens, the comparison of the crude invasive cancer detection rates for women aged 50-64 or all ages between programmes will be subject to confounding. This was a major problem in the earlier years of the national screening programme for prevalent screens, the most extreme case being one year in which the range in mean ages of women screened by individual programmes was 54 to 62, the expected rate of cancers being approximatelydouble in the latter case. The expected number of invasive cancers is obtained by multiplying the number of women screened by the expected rate in each age band and summing the total number of expected invasive cancers. The observed number of invasive cancers is read directly from the KC62 return. Table 6 shows an example SDR for first invitation to routine screening for the calculation shown below.
The reported number of invasive cancers, detected at first invitation to routine screening on the KC62 return was 16. The SDR is therefore 16/17.93 =0.89 or 89%. 101 To calculate the SDR for all prevalent screens, the observed and expected invasive cancers from the "first invitation to routine screening" and the "routine invitation to previous non-attenders" tables reported on the KC62 returns are added together.
The small invasive «15 mm) SDR is derived from the observation that the Swedish two county randomised controlled trial detected approximately 50% of invasive cancers at less than 15 mm. Therefore from the above example, if nine invasive cancers were detected with a size of less than 15 mm, the SDR would be 9/8.97 =
